Summit Therapeutics Inc
SMMT23.465USD
-13.235-36.06%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
17.31BMarket Cap
LossP/E TTM
More Details of Summit Therapeutics Inc Company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Company Info
Company codeSMMT
Company nameSummit Therapeutics Inc
IPO dateOct 14, 2004
Founded at2020
CEO- -
Number of employees159
Security typeOrdinary Share
Fiscal year-endOct 14
Address601 Brickell Key Drive
CityMIAMI
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code33131
Phone13052032034
Websitehttps://www.smmttx.com/
Company codeSMMT
IPO dateOct 14, 2004
Founded at2020
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Latin America
0.00
0.00%
By Business
By Region
No Data
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
Shareholder Statistics
Shareholder
Proportion
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
Type
Shareholder
Proportion
Individual Investor
84.90%
Investment Advisor
4.57%
Hedge Fund
4.06%
Investment Advisor/Hedge Fund
3.86%
Research Firm
0.40%
Pension Fund
0.02%
Bank and Trust
0.02%
Sovereign Wealth Fund
0.01%
Other
2.16%
Institutional Shareholding
Update time: Mon, Jan 20
Update time: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
388
717.78M
97.33%
+5.71M
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
2022Q4
154
191.34M
95.05%
+13.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Duggan (Robert William)
551.70M
74.81%
+3.33M
+0.61%
Sep 13, 2024
Zanganeh (Mahkam)
35.38M
4.8%
+84.32K
+0.24%
Apr 17, 2024
Xia (Yu)
31.52M
4.27%
--
--
Apr 17, 2024
Baker Bros. Advisors LP
24.42M
3.31%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
11.67M
1.58%
+724.04K
+6.61%
Dec 31, 2024
Fidelity Management & Research Company LLC
8.02M
1.09%
-277.94K
-3.35%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.55M
1.02%
+402.22K
+5.63%
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.47M
0.88%
+1.11M
+20.72%
Dec 31, 2024
State Street Global Advisors (US)
5.60M
0.76%
+2.13M
+61.54%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.20M
0.43%
+101.04K
+3.26%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Tema Oncology ETF
2.77%
Invesco Nasdaq Biotechnology ETF
1.46%
ProShares Ultra Nasdaq Biotechnology
1.42%
Range Cancer Immunotherapy ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
SPDR S&P Biotech ETF
0.92%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.67%
Direxion Daily S&P Biotech Bull 3X Shares
0.58%
Simplify Next Intangible Core Index ETF
0.35%
View more
Tema Oncology ETF
Proportion2.77%
Invesco Nasdaq Biotechnology ETF
Proportion1.46%
ProShares Ultra Nasdaq Biotechnology
Proportion1.42%
Range Cancer Immunotherapy ETF
Proportion1.24%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.04%
SPDR S&P Biotech ETF
Proportion0.92%
Invesco NASDAQ Next Gen 100 ETF
Proportion0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
Proportion0.67%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.58%
Simplify Next Intangible Core Index ETF
Proportion0.35%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data